Report Highlights

Human Milk Oligosaccharides in the U.S.: Competitive Overview

The U.S. HMO market is concentrated at the top of the value chain. Abbott Laboratories and Reckitt's Mead Johnson Nutrition control most branded infant formula volume, and both sell HMO-fortified lines as core products. Ingredient supply is less concentrated, with DSM-Firmenich, Jennewein Biotechnologie, and Kyowa Hakko Bio supplying fermented 2'-FL and LNnT, while Nestlé competes through its Gerber and specialty formula portfolio.

Domestic brands hold the advantage in retail access and regulatory fluency, while international producers hold the technical edge in fermentation. Winning here depends on FDA clearance for new HMO structures, shelf presence in mass retail and WIC-eligible channels, and reliable ingredient sourcing outside the U.S. Bobbie, a U.S. direct-to-consumer formula brand, has used clean-label positioning to win share from incumbents, proving that brand trust can offset scale gaps.

Demand Drivers Shaping U.S. HMO Adoption

Premium infant formula demand is the strongest driver. Higher-income households and parents seeking formulas that approximate breast milk favor Abbott, Reckitt, and Nestlé, whose premium lines carry HMO fortification at scale. Premium price points absorb the higher cost of fermented ingredients, and retail channels including Walmart and Target now stock tiered HMO-containing formulas, widening reach beyond specialty stores. Brands with established retail distribution therefore capture the volume growth.

Clinical and regulatory validation is the second driver. Research on 2'-FL and LNnT for gut microbiome development and immune support lowers the barrier to new product claims. Suppliers holding GRAS clearance gain first-mover advantage, while the 2022 Abbott Sturgis recall pushed parents toward alternative brands and accelerated HMO-fortified launches by competitors seeking share recovery. Late entrants face months of documentation work before commercial launch.

Competitive Restraints and Market Challenges

Private-label competition constrains margins. Retailer brands sold through Walmart, Costco, and Target now include HMO-fortified options, compressing the premium branded players earned on HMO ingredients. Brands that cannot cut ingredient costs through scale fermentation will lose shelf positions in mass channels, where price comparison is immediate and shoppers switch quickly between tiers. Perrigo's contract manufacturing for private-label formula amplifies this pressure across retailer portfolios.

Compliance costs and talent gaps raise barriers for smaller entrants. FDA requirements under 21 CFR Part 107 and the ongoing Operation Stork Speed nutrient review add testing and documentation expenses before any product reaches shelves. Fermentation scientists and downstream purification specialists are scarce in the U.S., and domestic bioprocessing capacity trails demand, leaving manufacturers dependent on imported intermediates. That dependence exposes margins to tariff changes on European and Asian shipments.

Growth Opportunities for Market Players

Domestic fermentation capacity offers the largest opportunity. Companies that establish or contract U.S.-based 2'-FL and LNT production capture supply-security premiums from formula manufacturers seeking to reduce import exposure. Contract manufacturing partnerships with Midwest facilities give new entrants a route to market without full capital outlays, and early movers win multi-year offtake agreements with national brands.

Adult and medical nutrition extensions offer a second opportunity. Preterm infant formulas, adult gut-health supplements, and HMO-based functional foods are areas where Nestlé Health Science and Abbott's nutrition units can extend HMO use beyond infant formula. Companies that secure clinical evidence and regulatory clearance for adult claims early will own a category with few incumbent claims. Sports and senior nutrition represent adjacent segments where competition remains fragmented.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Reckitt
• Nestlé
• DSM-Firmenich
• Novonesis
• Jennewein Biotechnologie
• Kyowa Hakko Bio
• Perrigo Company
• Bobbie
• Inbiose

Regulatory and Policy Environment

The FDA regulates infant formula under the Federal Food, Drug, and Cosmetic Act and 21 CFR Part 107, which sets nutrient requirements HMO-fortified products must satisfy. Ingredient producers enter the market through GRAS notifications, and FDA no-questions letters for 2'-FL and LNnT established the clearance pathway competitors now follow. Operation Stork Speed, launched by the FDA in 2025, is reviewing infant formula nutrient requirements, and its outcome will reset formulation rules for every HMO brand.

The Access to Baby Formula Act of 2022 expanded FDA oversight of formula supply chains and supported supply-chain resilience measures. USDA WIC program eligibility rules determine which formula products reach low-income households, making WIC contract awards a decisive competitive lever for Abbott and Reckitt. Tariff policy on imported ingredients from the EU and China also affects landed costs for every HMO producer serving U.S. formula manufacturers. Compliance with these rules sets the minimum standard for market entry.

Competitive Outlook for HMOs in the U.S.

By 2032 the market will move toward a structure where ingredient producers capture more value. Fermentation specialists such as DSM-Firmenich, Novonesis, and Jennewein Biotechnologie will expand U.S. partnerships, while formula brands compete through exclusive supply contracts rather than owning ingredient production. Consolidation among smaller infant nutrition startups will accelerate as capital requirements for regulatory filings and bioprocessing rise. Retailer private labels will hold a growing share of mass-market HMO volume.

Competitive advantage by 2032 will rest on three factors: secured ingredient supply, clinical evidence for adult and preterm claims, and deep retail distribution. Abbott and Reckitt retain scale leadership, while Bobbie and Perrigo's private-label expansion test whether brand loyalty survives price pressure. Players combining domestic supply resilience with validated clinical claims will hold the strongest positions through the forecast period. Market share shifts will favor firms that move early on U.S. fermentation investment.